Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma

Wenna Nie, Leyu Yan, Yie H. Lee, Chandan Guha, Irwin J. Kurland, Haitao Lu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the primary hepatic malignancies and is the third most common cause of cancer related death worldwide. Although a wealth of knowledge has been gained concerning the initiation and progression of HCC over the last half century, efforts to improve our understanding of its pathogenesis at a molecular level are still greatly needed, to enable clinicians to enhance the standards of the current diagnosis and treatment of HCC. In the post-genome era, advanced mass spectrometry driven multi-omics technologies (e.g., profiling of DNA damage adducts, RNA modification profiling, proteomics, and metabolomics) stand at the interface between chemistry and biology, and have yielded valuable outcomes from the study of a diversity of complicated diseases. Particularly, these technologies are being broadly used to dissect various biological aspects of HCC with the purpose of biomarker discovery, interrogating pathogenesis as well as for therapeutic discovery. This proof of knowledge-based critical review aims at exploring the selected applications of those defined omics technologies in the HCC niche with an emphasis on translational applications driven by advanced mass spectrometry, toward the specific clinical use for HCC patients. This approach will enable the biomedical community, through both basic research and the clinical sciences, to enhance the applicability of mass spectrometry-based omics technologies in dissecting the pathogenesis of HCC and could lead to novel therapeutic discoveries for HCC.

Original languageEnglish (US)
JournalMass Spectrometry Reviews
DOIs
StateAccepted/In press - 2014

Fingerprint

pathogenesis
Mass spectrometry
Hepatocellular Carcinoma
Mass Spectrometry
mass spectroscopy
cancer
Technology
Biomarkers
Genes
RNA
Metabolomics
DNA Adducts
DNA
genome
biomarkers
Proteomics
DNA Damage
biology
death
progressions

Keywords

  • DNA damage adducts
  • Hepatocellular carcinoma
  • Metabolomics
  • Omics technology
  • Proteomics
  • RNA modifications

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Spectroscopy
  • Analytical Chemistry
  • Condensed Matter Physics

Cite this

@article{e57fadf559db4ab5a4bd2d0f51285d14,
title = "Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is one of the primary hepatic malignancies and is the third most common cause of cancer related death worldwide. Although a wealth of knowledge has been gained concerning the initiation and progression of HCC over the last half century, efforts to improve our understanding of its pathogenesis at a molecular level are still greatly needed, to enable clinicians to enhance the standards of the current diagnosis and treatment of HCC. In the post-genome era, advanced mass spectrometry driven multi-omics technologies (e.g., profiling of DNA damage adducts, RNA modification profiling, proteomics, and metabolomics) stand at the interface between chemistry and biology, and have yielded valuable outcomes from the study of a diversity of complicated diseases. Particularly, these technologies are being broadly used to dissect various biological aspects of HCC with the purpose of biomarker discovery, interrogating pathogenesis as well as for therapeutic discovery. This proof of knowledge-based critical review aims at exploring the selected applications of those defined omics technologies in the HCC niche with an emphasis on translational applications driven by advanced mass spectrometry, toward the specific clinical use for HCC patients. This approach will enable the biomedical community, through both basic research and the clinical sciences, to enhance the applicability of mass spectrometry-based omics technologies in dissecting the pathogenesis of HCC and could lead to novel therapeutic discoveries for HCC.",
keywords = "DNA damage adducts, Hepatocellular carcinoma, Metabolomics, Omics technology, Proteomics, RNA modifications",
author = "Wenna Nie and Leyu Yan and Lee, {Yie H.} and Chandan Guha and Kurland, {Irwin J.} and Haitao Lu",
year = "2014",
doi = "10.1002/mas.21439",
language = "English (US)",
journal = "Mass Spectrometry Reviews",
issn = "0277-7037",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma

AU - Nie, Wenna

AU - Yan, Leyu

AU - Lee, Yie H.

AU - Guha, Chandan

AU - Kurland, Irwin J.

AU - Lu, Haitao

PY - 2014

Y1 - 2014

N2 - Hepatocellular carcinoma (HCC) is one of the primary hepatic malignancies and is the third most common cause of cancer related death worldwide. Although a wealth of knowledge has been gained concerning the initiation and progression of HCC over the last half century, efforts to improve our understanding of its pathogenesis at a molecular level are still greatly needed, to enable clinicians to enhance the standards of the current diagnosis and treatment of HCC. In the post-genome era, advanced mass spectrometry driven multi-omics technologies (e.g., profiling of DNA damage adducts, RNA modification profiling, proteomics, and metabolomics) stand at the interface between chemistry and biology, and have yielded valuable outcomes from the study of a diversity of complicated diseases. Particularly, these technologies are being broadly used to dissect various biological aspects of HCC with the purpose of biomarker discovery, interrogating pathogenesis as well as for therapeutic discovery. This proof of knowledge-based critical review aims at exploring the selected applications of those defined omics technologies in the HCC niche with an emphasis on translational applications driven by advanced mass spectrometry, toward the specific clinical use for HCC patients. This approach will enable the biomedical community, through both basic research and the clinical sciences, to enhance the applicability of mass spectrometry-based omics technologies in dissecting the pathogenesis of HCC and could lead to novel therapeutic discoveries for HCC.

AB - Hepatocellular carcinoma (HCC) is one of the primary hepatic malignancies and is the third most common cause of cancer related death worldwide. Although a wealth of knowledge has been gained concerning the initiation and progression of HCC over the last half century, efforts to improve our understanding of its pathogenesis at a molecular level are still greatly needed, to enable clinicians to enhance the standards of the current diagnosis and treatment of HCC. In the post-genome era, advanced mass spectrometry driven multi-omics technologies (e.g., profiling of DNA damage adducts, RNA modification profiling, proteomics, and metabolomics) stand at the interface between chemistry and biology, and have yielded valuable outcomes from the study of a diversity of complicated diseases. Particularly, these technologies are being broadly used to dissect various biological aspects of HCC with the purpose of biomarker discovery, interrogating pathogenesis as well as for therapeutic discovery. This proof of knowledge-based critical review aims at exploring the selected applications of those defined omics technologies in the HCC niche with an emphasis on translational applications driven by advanced mass spectrometry, toward the specific clinical use for HCC patients. This approach will enable the biomedical community, through both basic research and the clinical sciences, to enhance the applicability of mass spectrometry-based omics technologies in dissecting the pathogenesis of HCC and could lead to novel therapeutic discoveries for HCC.

KW - DNA damage adducts

KW - Hepatocellular carcinoma

KW - Metabolomics

KW - Omics technology

KW - Proteomics

KW - RNA modifications

UR - http://www.scopus.com/inward/record.url?scp=84901738126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901738126&partnerID=8YFLogxK

U2 - 10.1002/mas.21439

DO - 10.1002/mas.21439

M3 - Article

JO - Mass Spectrometry Reviews

JF - Mass Spectrometry Reviews

SN - 0277-7037

ER -